ASND and A1SN34 Related Headlines
Go Back- Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Liberty All-Star® Growth Fund, Inc. January 2026 Monthly Update
- Liberty All-Star® Growth Fund, Inc. January 2026 Monthly Update
- The Boston Globe to Host Rare Disease Summit
- BioNJ Elects Board Officers and Trustees
- Liberty All-Star® Growth Fund, Inc. December 2025 Monthly Update
- Liberty All-Star® Growth Fund, Inc. November 2025 Monthly Update
- Alva Therapeutics appoints former Novo Nordisk executive to board
- Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
- Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update
- Liberty All-Star® Growth Fund, Inc. September 2025 Monthly Update
- Liberty All-Star® Growth Fund, Inc. August 2025 Monthly Update
- Liberty All-Star® Growth Fund, Inc. July 2025 Monthly Update
- National Organization for Rare Disorders (NORD) Announces 2025 Industry Innovation and Rare Impact Award Honorees
- Liberty All-Star® Growth Fund, Inc. June 2025 Monthly Update
- Dr. Jethro Ekuta Joins BP Logix Life Sciences Strategic Advisory Board
ASND and A1SN34 Related Press Releases
Go Back- Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Liberty All-Star® Growth Fund, Inc. January 2026 Monthly Update
- Liberty All-Star® Growth Fund, Inc. January 2026 Monthly Update
- The Boston Globe to Host Rare Disease Summit
- BioNJ Elects Board Officers and Trustees
- Liberty All-Star® Growth Fund, Inc. December 2025 Monthly Update
- Liberty All-Star® Growth Fund, Inc. November 2025 Monthly Update
- Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
- Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update
- Liberty All-Star® Growth Fund, Inc. September 2025 Monthly Update
- Liberty All-Star® Growth Fund, Inc. August 2025 Monthly Update
- Liberty All-Star® Growth Fund, Inc. July 2025 Monthly Update
- National Organization for Rare Disorders (NORD) Announces 2025 Industry Innovation and Rare Impact Award Honorees
- Liberty All-Star® Growth Fund, Inc. June 2025 Monthly Update
- Dr. Jethro Ekuta Joins BP Logix Life Sciences Strategic Advisory Board
ASND and A1SN34 Related SEC Filings
Go Back- Form 144 Ascendis Pharma A/S Filed by: Bodenhoff Mads
- Form 144/A Ascendis Pharma A/S Filed by: SMITH SCOTT THOMAS
- Form 144 Ascendis Pharma A/S Filed by: Shu Aimee
- Form 144 Ascendis Pharma A/S Filed by: SMITH SCOTT THOMAS
- Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
- Form 144 Ascendis Pharma A/S Filed by: Morrison Lisa
- Form 144 Ascendis Pharma A/S Filed by: Shu Aimee
- Form 144 Ascendis Pharma A/S Filed by: Fairey William
- Form 144 Ascendis Pharma A/S Filed by: IMANI SIHAM
- Form 144 Ascendis Pharma A/S Filed by: SMITH SCOTT THOMAS
- Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
- Form 144 Ascendis Pharma A/S Filed by: Bodenhoff Mads
- Form 144 Ascendis Pharma A/S Filed by: PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG
- Form 144 Ascendis Pharma A/S Filed by: Morrison Lisa
- Form 144 Ascendis Pharma A/S Filed by: HOLTUG LARS
- Form 144 Ascendis Pharma A/S Filed by: SPROGOE KENNETT
- Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
- Form 144 Ascendis Pharma A/S Filed by: Cha Albert
- Form 6-K Ascendis Pharma A/S For: Feb 28
- Form S-8 Ascendis Pharma A/S
- Form 6-K Ascendis Pharma A/S For: Feb 23
- Form 6-K Ascendis Pharma A/S For: Feb 11
- Form 20-F Ascendis Pharma A/S For: Dec 31
- Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: WESTFIELD CAPITAL MANAGEMENT CO LP
- Form 6-K Ascendis Pharma A/S For: Feb 10
- Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: Artisan Partners Limited Partnership
- Form 6-K Ascendis Pharma A/S For: Jan 14
- Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
- Form 6-K Ascendis Pharma A/S For: Jan 12
- Form 6-K Ascendis Pharma A/S For: Jan 08
- Form 6-K Ascendis Pharma A/S For: Dec 30
- Form 6-K Ascendis Pharma A/S For: Dec 10
- Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
- Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
- Form 144 Ascendis Pharma A/S Filed by: SPROGOE KENNETT
- Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
- Form 144 Ascendis Pharma A/S Filed by: SINGEL STINA
- Form 6-K Ascendis Pharma A/S For: Nov 25
- Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc.
- Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: JANUS HENDERSON GROUP PLC
- Form 6-K Ascendis Pharma A/S For: Nov 12
- Form 6-K Ascendis Pharma A/S For: Sep 30
- Form 6-K Ascendis Pharma A/S For: Nov 12
- Form 6-K Ascendis Pharma A/S For: Oct 22
- Form 6-K Ascendis Pharma A/S For: Oct 15
- Form 6-K Ascendis Pharma A/S For: Oct 08
- Form 6-K Ascendis Pharma A/S For: Sep 30
- Form 6-K Ascendis Pharma A/S For: Sep 10
- Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
- Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
- Form 144 Ascendis Pharma A/S Filed by: PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG
- Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
- Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
- Form 144 Ascendis Pharma A/S Filed by: PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG
- Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: T. Rowe Price Investment Management, Inc.
- Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: JANUS HENDERSON GROUP PLC
- Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
- Form 144 Ascendis Pharma A/S Filed by: Morrison Lisa
- Form 6-K Ascendis Pharma A/S For: Aug 13
- Form SCHEDULE 13G Ascendis Pharma A/S Filed by: Capital International Investors
- Form 144 Ascendis Pharma A/S Filed by: SMITH SCOTT THOMAS
- Form 6-K Ascendis Pharma A/S For: Jun 30
- Form 6-K Ascendis Pharma A/S For: Aug 07
- Form 6-K Ascendis Pharma A/S For: Jul 28
- Form 6-K Ascendis Pharma A/S For: Jul 09
- Form 6-K Ascendis Pharma A/S For: Jun 27
- Form 6-K Ascendis Pharma A/S For: Jun 11

